Bovine Respiratory Disease Complex: Bacterial Pathogens and Antimicrobial Management

Introduction

Bovine Respiratory Disease Complex (BRDC) represents the most economically significant infectious disease syndrome affecting feedlot cattle worldwide. The condition arises from a multifactorial interplay between host immune status, environmental stressors, viral priming agents, and bacterial pathogens. The bacterial component of BRDC is dominated by three primary agents: Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. These organisms colonize the upper respiratory tract as commensals and, under conditions of immunosuppression or viral coinfection, translocate to the lower airways to initiate fibrinous bronchopneumonia. The pathogenesis, diagnostic approaches, and antimicrobial management of these bacterial pathogens are the focus of this review.

Primary Bacterial Pathogens

Mannheimia haemolytica

Mannheimia haemolytica (formerly Pasteurella haemolytica biotype A serotype 1) is the most frequently isolated bacterial pathogen from acute cases of BRDC [1, 2]. The organism is a Gram-negative coccobacillus that colonizes the nasopharynx and tonsillar crypts of healthy cattle. Serotype A1 is the predominant serotype associated with clinical disease, although serotypes A2, A6, and A9 are also recovered from pneumonic lungs [3].

The primary virulence factor of M. haemolytica is a leukotoxin (LktA) belonging to the repeats-in-toxin (RTX) family. Leukotoxin binds to the CD18 subunit of beta-2 integrins on bovine leukocytes, inducing apoptosis and necrosis of alveolar macrophages and neutrophils [4, 5]. This cytolytic activity releases proinflammatory cytokines and proteolytic enzymes that damage pulmonary parenchyma. Additional virulence determinants include a polysaccharide capsule that inhibits phagocytosis, lipopolysaccharide (LPS) that triggers the acute-phase response, and outer membrane proteins (OMPs) involved in iron acquisition and adhesion to respiratory epithelium [6, 7].

Pasteurella multocida

Pasteurella multocida is a Gram-negative coccobacillus that is frequently isolated from both healthy carriers and cattle with BRDC. Capsular serogroup A (hyaluronic acid capsule) and somatic serotype 3 are most commonly associated with bovine respiratory disease [8]. Unlike M. haemolytica, P. multocida does not produce a leukotoxin; its pathogenicity relies on capsular polysaccharides, LPS, and a variety of adhesins including filamentous hemagglutinin and type IV fimbriae [9].

P. multocida is often considered a secondary invader that proliferates following viral damage to the respiratory epithelium. The organism induces a suppurative bronchopneumonia characterized by neutrophil infiltration and exudation into airways [10]. Coinfection with M. haemolytica or H. somni is common and is associated with more severe clinical outcomes [11].

Histophilus somni

Histophilus somni (formerly Haemophilus somnus) is a Gram-negative coccobacillus that causes a distinct clinical syndrome within BRDC known as thrombotic meningoencephalomyelitis (TME), in addition to pneumonia, myocarditis, and reproductive tract infections [12, 13]. The organism is a fastidious, capnophilic bacterium that requires enriched media for isolation.

The major virulence factor of H. somni is a phase-variable lipooligosaccharide (LOS) that undergoes antigenic variation to evade host immune responses [14]. H. somni also produces an immunoglobulin-binding protein (IbpA) that interferes with Fc receptor-mediated phagocytosis, and a fibronectin-binding protein that facilitates adherence to endothelial cells [15]. The ability of H. somni to survive within phagocytic cells contributes to its capacity to cause systemic infections [16].

Pathogenesis and Host-Pathogen Interactions

The progression from nasopharyngeal colonization to lower respiratory tract disease requires a breach in host defense mechanisms. Viral infections, particularly with bovine respiratory syncytial virus (BRSV), bovine parainfluenza virus type 3 (BPIV-3), bovine herpesvirus type 1 (BHV-1), and bovine viral diarrhea virus (BVDV), impair mucociliary clearance, damage epithelial integrity, and suppress alveolar macrophage function [17, 18]. Stressors such as weaning, transport, commingling, and castration elevate circulating cortisol levels, which further suppress neutrophil and lymphocyte function [19].

Following viral insult, bacterial pathogens proliferate in the upper airways and are aspirated into the lower respiratory tract. The resulting inflammatory cascade involves the release of interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-alpha), and leukotriene B4, which recruit neutrophils to the alveoli [20]. In the case of M. haemolytica, leukotoxin-mediated neutrophil lysis releases DNA, actin, and histones that form neutrophil extracellular traps (NETs), contributing to airway obstruction and consolidation [21].

The hallmark lesion of BRDC is fibrinous bronchopneumonia with cranioventral distribution. Histologically, the lung exhibits necrosis of alveolar septa, fibrin exudation, and infiltration of degenerate neutrophils [22]. In H. somni infections, vasculitis and thrombosis of pulmonary capillaries are prominent features, often accompanied by systemic dissemination to the central nervous system [23].

Clinical Diagnosis

Clinical diagnosis of BRDC relies on the observation of depression, anorexia, nasal discharge, ocular discharge, cough, dyspnea, and fever (rectal temperature exceeding 39.7 degrees Celsius) [24]. A clinical scoring system, such as the DART (Depression, Appetite, Respiratory, Temperature) system, is used in feedlot settings to identify animals requiring treatment [25].

Definitive etiologic diagnosis requires collection of specimens from the lower respiratory tract. Transtracheal aspiration (TTA) and bronchoalveolar lavage (BAL) are the preferred sampling methods for bacterial culture and susceptibility testing [26]. Nasal swabs are not recommended for bacterial diagnosis due to poor correlation with lower airway flora [27].

Bacterial culture on blood agar and chocolate agar under 5-10% carbon dioxide at 35-37 degrees Celsius yields growth within 24-48 hours. M. haemolytica appears as small, gray colonies with a characteristic sweet odor and is positive for oxidase and catalase. P. multocida produces indole and is positive for ornithine decarboxylase. H. somni requires carbon dioxide enrichment and appears as small, dewdrop colonies that are positive for oxidase and negative for catalase [28].

Molecular diagnostics, including multiplex polymerase chain reaction (PCR) panels, offer rapid detection and differentiation of BRDC bacterial pathogens directly from respiratory specimens [29]. Quantitative PCR (qPCR) assays targeting the lktA gene of M. haemolytica, the kmt1 gene of P. multocida, and the 16S rRNA gene of H. somni provide high sensitivity and specificity [30]. The use of metagenomic sequencing for comprehensive pathogen detection and antimicrobial resistance gene profiling is an emerging approach in BRDC diagnostics [31].

Antimicrobial Resistance Patterns

Antimicrobial resistance (AMR) among BRDC bacterial pathogens is a growing concern. Resistance to tetracyclines, macrolides, and florfenicol has been documented in M. haemolytica and P. multocida isolates from feedlot cattle across North America [32, 33].

Mechanisms of Resistance

Resistance to tetracyclines is mediated primarily by ribosomal protection proteins encoded by tet(H) and tet(G) genes, which are often carried on mobile genetic elements [34]. Macrolide resistance in M. haemolytica is associated with the erm(42) gene, encoding a ribosomal methylase that modifies the 23S rRNA target site, and the msr(E)-mph(E) gene cassette, encoding an efflux pump and a phosphotransferase, respectively [35, 36]. Florfenicol resistance is conferred by the floR gene, which encodes an exporter protein belonging to the major facilitator superfamily [37].

Prevalence Data

Surveillance studies from the United States and Canada report that resistance to oxytetracycline exceeds 40% in M. haemolytica isolates, while resistance to tilmicosin and tulathromycin ranges from 10% to 30% [38, 39]. Multidrug resistance, defined as resistance to three or more antimicrobial classes, is detected in 15-25% of M. haemolytica isolates [40]. P. multocida isolates generally exhibit lower resistance frequencies, although resistance to sulfonamides and tetracyclines is common [41]. H. somni isolates have historically been more susceptible, but reports of beta-lactamase production and reduced susceptibility to macrolides are increasing [42].

Antimicrobial Management

Antimicrobial therapy for BRDC should be guided by culture and susceptibility testing whenever possible. Empirical treatment is often initiated based on the expected pathogen profile and local resistance patterns.

Approved Antimicrobial Classes

Several antimicrobial classes are approved for the treatment of BRDC in cattle:

• Tetracyclines: Oxytetracycline is a broad-spectrum bacteriostatic agent commonly used for metaphylaxis and treatment. Resistance is widespread, limiting its efficacy in some populations [43].
• Macrolides: Tilmicosin, tulathromycin, and gamithromycin are concentration-dependent bactericidal agents with excellent activity against M. haemolytica and P. multocida. Tulathromycin has a long elimination half-life, allowing single-dose therapy [44].
• Florfenicol: A bacteriostatic agent that inhibits protein synthesis at the 50S ribosomal subunit. It is effective against M. haemolytica, P. multocida, and H. somni [45].
• Cephalosporins: Ceftiofur is a third-generation cephalosporin with activity against Gram-negative respiratory pathogens. It is available as ceftiofur sodium, ceftiofur hydrochloride, and ceftiofur crystalline free acid [46].
• Fluoroquinolones: Enrofloxacin and danofloxacin are concentration-dependent bactericidal agents with excellent tissue penetration. Their use is restricted in some jurisdictions due to concerns about resistance development [47].

Treatment Guidelines

The selection of an antimicrobial agent should consider the following factors: pathogen susceptibility, pharmacokinetic and pharmacodynamic properties, withdrawal times, cost, and regulatory constraints. The following table summarizes the recommended antimicrobials for BRDC bacterial pathogens:

Metaphylaxis

Metaphylaxis, the mass administration of antimicrobials to high-risk cattle upon arrival at the feedlot, is a common practice to reduce BRDC incidence. Tulathromycin and tilmicosin are the most frequently used metaphylactic agents [48]. While metaphylaxis reduces morbidity and mortality, it exerts selective pressure for AMR and is a target of antimicrobial stewardship programs [49].

Antimicrobial Stewardship

Antimicrobial stewardship in BRDC management involves the following principles: accurate diagnosis, targeted therapy based on culture and susceptibility results, appropriate dosing and duration, and avoidance of unnecessary metaphylaxis. The use of rapid diagnostic tests, including PCR panels and antimicrobial susceptibility testing directly from clinical specimens, enables more precise antimicrobial selection [50].

Decision Tree for BRDC Diagnosis and Treatment

The following Mermaid diagram illustrates a clinical decision tree for the diagnosis and antimicrobial management of BRDC:

flowchart TD
    A[Clinical Signs: Fever, Depression, Dyspnea], > B{Clinical Score >= Threshold?}
    B, >|Yes| C[Collect TTA or BAL Sample]
    B, >|No| D[Monitor and Reassess]
    C, > E[Submit for Bacterial Culture and PCR]
    E, > F{Pathogen Identified?}
    F, >|M. haemolytica| G[Antimicrobial Susceptibility Testing]
    F, >|P. multocida| G
    F, >|H. somni| G
    F, >|No Pathogen| H[Consider Viral or Non-Infectious Etiology]
    G, > I{Susceptibility Pattern}
    I, >|Susceptible to First-Line| J[Treat with Tulathromycin or Florfenicol]
    I, >|Resistant to First-Line| K[Treat with Ceftiofur or Enrofloxacin]
    J, > L[Reassess at 48-72 Hours]
    K, > L
    L, > M{Clinical Improvement?}
    M, >|Yes| N[Complete Course]
    M, >|No| O[Repeat Culture and Susceptibility]
    O, > P[Adjust Antimicrobial Based on Results]

Future Directions

The integration of metagenomic sequencing and bioinformatics into BRDC diagnostics offers the potential for comprehensive pathogen detection, virulence gene profiling, and AMR gene surveillance. Computational models that predict antimicrobial susceptibility from genomic data are under development and may reduce the turnaround time for targeted therapy. Additionally, the development of vaccines targeting conserved antigens across multiple M. haemolytica serotypes and H. somni strains could reduce the reliance on antimicrobials for BRDC control.

References

[1] Rice JA, Carrasco-Medina L, Hodgins DC, Shewen PE. Mannheimia haemolytica and bovine respiratory disease. Anim Health Res Rev. 2007;8(2):117-128.

[2] Griffin D. Economic impact associated with respiratory disease in beef cattle. Vet Clin North Am Food Anim Pract. 1997;13(3):367-377.

[3] Klima CL, Zaheer R, Cook SR, et al. Pathogens of bovine respiratory disease in North American feedlots conferring multidrug resistance via integrative conjugative elements. J Clin Microbiol. 2014;52(2):438-448.

[4] Highlander SK. Molecular genetic analysis of virulence in Mannheimia haemolytica. Front Biosci. 2001;6:D1128-D1150.

[5] Jeyaseelan S, Sreevatsan S, Maheswaran SK. Role of Mannheimia haemolytica leukotoxin in the pathogenesis of bovine pneumonic pasteurellosis. Anim Health Res Rev. 2002;3(2):69-82.

[6] Lo RY. Genetic analysis of virulence factors of Mannheimia haemolytica A1. Vet Microbiol. 2001;83(3):225-235.

[7] Confer AW, Ayalew S. Mannheimia haemolytica in bovine respiratory disease: immunogens, potential immunogens, and vaccines. Anim Health Res Rev. 2018;19(2):79-99.

[8] Harper M, Boyce JD, Adler B. Pasteurella multocida pathogenesis: 125 years after Pasteur. FEMS Microbiol Lett. 2006;265(1):1-10.

[9] Wilkie IW, Harper M, Boyce JD, Adler B. Pasteurella multocida: diseases and pathogenesis. Curr Top Microbiol Immunol. 2012;361:1-22.

[10] Dabo SM, Taylor JD, Confer AW. Pasteurella multocida and bovine respiratory disease. Anim Health Res Rev. 2007;8(2):129-150.

[11] Booker CW, Abutarbush SM, Morley PS, et al. Microbiological and histopathological findings in cases of fatal bovine respiratory disease in feedlot cattle. Can Vet J. 2008;49(5):473-481.

[12] Corbeil LB. Histophilus somni host-parasite relationships. Anim Health Res Rev. 2007;8(2):151-160.

[13] Harris FW, Janzen ED. The Haemophilus somnus disease complex (Haemophilosis): a review. Can Vet J. 1989;30(10):816-822.

[14] Inzana TJ, Glindemann G, Cox AD, et al. Incorporation of N-acetylneuraminic acid into Haemophilus somnus lipooligosaccharide. Infect Immun. 2002;70(9):4872-4879.

[15] Tagawa Y, Haritani M, Ishikawa H, Yuasa N. Characterization of a heat-modifiable outer membrane protein of Haemophilus somnus. Infect Immun. 1993;61(5):1750-1755.

[16] Lederer JA, Brown JF, Czuprynski CJ. Haemophilus somnus, a cause of bovine respiratory disease: a review. Vet Bull. 1987;57:571-580.

[17] Fulton RW, Confer AW, Burge LJ, et al. Bovine viral diarrhea virus and bovine respiratory syncytial virus infections in feedlot cattle. Vet Clin North Am Food Anim Pract. 1997;13(3):447-460.

[18] Gagea MI, Bateman KG, van Dreumel T, et al. Diseases and pathogens associated with mortality in Ontario beef feedlots. J Vet Diagn Invest. 2006;18(1):18-28.

[19] Duff GC, Galyean ML. Board-invited review: recent advances in management of highly stressed, newly received feedlot cattle. J Anim Sci. 2007;85(3):823-840.

[20] Caswell JL, Williams KJ. Respiratory system. In: Maxie MG, ed. Jubb, Kennedy, and Palmer's Pathology of Domestic Animals. 6th ed. Elsevier; 2016:465-591.

[21] Aulik NA, Hellenbrand KM, Czuprynski CJ. Mannheimia haemolytica leukotoxin binds to bovine peripheral blood neutrophils and induces formation of neutrophil extracellular traps. Infect Immun. 2010;78(11):4780-4788.

[22] Lopez A. Respiratory system, thoracic cavity, and pleura. In: McGavin MD, Zachary JF, eds. Pathologic Basis of Veterinary Disease. 4th ed. Mosby; 2007:463-558.

[23] Van Donkersgoed J, Janzen ED, Harland RJ. Epidemiological features of calf mortality due to hemophilosis in a large feedlot. Can Vet J. 1990;31(11):791-795.

[24] Smith RA. Impact of disease on feedlot performance: a review. J Anim Sci. 1998;76(1):272-274.

[25] Step DL, Krehbiel CR, DePra HA, et al. Effects of commingling beef calves from different sources and weaning protocols on animal health and performance. J Anim Sci. 2008;86(10):2673-2682.

[26] Allen JW, Viel L, Bateman KG, et al. The microbial flora of the respiratory tract in feedlot calves: associations between nasopharyngeal and bronchoalveolar lavage cultures. Can J Vet Res. 1991;55(4):341-346.

[27] DeRosa DC, Mechor GD, Staats JJ, et al. Comparison of Pasteurella spp. isolated from the upper and lower respiratory tract of cattle with shipping fever. J Vet Diagn Invest. 2000;12(3):266-269.

[28] Quinn PJ, Markey BK, Leonard FC, et al. Veterinary Microbiology and Microbial Disease. 2nd ed. Wiley-Blackwell; 2011.

[29] Bell CJ, Blackburn P, Elliott M, et al. Investigation of polymerase chain reaction assays to improve detection of bacterial pathogens of bovine respiratory disease. J Vet Diagn Invest. 2014;26(2):247-254.

[30] Hille M, van der Meer F, van der Heijden HM, et al. Development and validation of a multiplex real-time PCR for detection of bacterial pathogens associated with bovine respiratory disease. J Vet Diagn Invest. 2016;28(4):394-402.

[31] Timsit E, Workentine M, van der Meer F, Alexander TW. Distinct bacterial metacommunities inhabit the upper and lower respiratory tracts of healthy feedlot cattle. FEMS Microbiol Ecol. 2017;93(8):fix107.

[32] Portis E, Lindeman C, Johansen L, Stoltman G. A ten-year (2000-2009) study of antimicrobial susceptibility of bacteria that cause bovine respiratory disease complex in the United States. Vet Ther. 2012;13(1):E1-E18.

[33] Lubbers BV, Hanzlicek GA. Antimicrobial multidrug resistance and coresistance patterns of Mannheimia haemolytica isolated from bovine respiratory disease cases in a Kansas feedlot. J Vet Diagn Invest. 2013;25(6):757-761.

[34] Kehrenberg C, Schwarz S. Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob Agents Chemother. 2006;50(4):1156-1163.

[35] Desmolaize B, Rose S, Warrass R, Douthwaite S. A novel Erm monomethyltransferase in antibiotic-resistant isolates of Mannheimia haemolytica and Pasteurella multocida. Mol Microbiol. 2011;80(5):1301-1310.

[36] Kadlec K, Schwarz S. Novel ABC transporter gene, vga(C), located on a multiresistance plasmid from a porcine methicillin-resistant Staphylococcus aureus ST398 strain. Antimicrob Agents Chemother. 2009;53(8):3589-3591.

[37] Kehrenberg C, Schwarz S. fexA, a novel Staphylococcus lentus gene encoding resistance to florfenicol and chloramphenicol. Antimicrob Agents Chemother. 2004;48(2):615-618.

[38] Klima CL, Zaheer R, Cook SR, et al. Pathogens of bovine respiratory disease in North American feedlots conferring multidrug resistance via integrative conjugative elements. J Clin Microbiol. 2014;52(2):438-448.

[39] Anholt RM, Klima C, Allan N, et al. Antimicrobial susceptibility of bacteria that cause bovine respiratory disease complex in Alberta, Canada. Front Vet Sci. 2017;4:207.

[40] Snyder E, Credille B, Berghaus R, Giguere S. Prevalence of multi drug antimicrobial resistance in Mannheimia haemolytica isolated from high-risk stocker cattle at arrival and after treatment. J Anim Sci. 2017;95(7):3124-3132.

[41] Watts JL, Yancey RJ, Salmon SA, Case CA. A 4-year survey of antimicrobial susceptibility trends for isolates from cattle with bovine respiratory disease in North America. J Clin Microbiol. 1994;32(3):725-731.

[42] Corbeil LB, Gogolewski RP, Stephens LR, Inzana TJ. Haemophilus somnus: antigen analysis and immune responses. In: Donachie W, Lainson FA, Hodgson JC, eds. Haemophilus, Actinobacillus, and Pasteurella. Plenum Press; 1995:63-73.

[43] Mechor GD, Jim GK, Janzen ED. Comparison of oxytetracycline and tilmicosin for the treatment of undifferentiated bovine respiratory disease in feedlot calves. Can Vet J. 1988;29(12):987-990.

[44] Nowakowski MA, Inskeep PB, Risk JE, et al. Pharmacokinetics and lung tissue concentrations of tulathromycin, a new triamilide antibiotic, in cattle. J Vet Pharmacol Ther. 2004;27(1):53-58.

[45] Varma KJ, Lockwood PW, Cosgrove SB, et al. Pharmacokinetics of florfenicol in cattle. J Vet Pharmacol Ther. 1998;21(5):353-361.

[46] Hornish RE, Kotarski SF. Cephalosporins in veterinary medicine: ceftiofur use in food animals. Curr Top Med Chem. 2002;2(7):717-731.

[47] McKellar QA, Sanchez Bruni SF, Jones DG. Pharmacokinetic and pharmacodynamic considerations for the use of fluoroquinolones in cattle. Vet J. 2004;168(1):10-21.

[48] Nickell JS, White BJ. Metaphylactic antimicrobial therapy for bovine respiratory disease in stocker and feedlot cattle. Vet Clin North Am Food Anim Pract. 2010;26(2):285-301.

[49] Weese JS, Giguere S, Guardabassi L, et al. ACVIM consensus statement on therapeutic antimicrobial use in animals and antimicrobial resistance. J Vet Intern Med. 2015;29(2):487-498.

[50] Apley MD. Antimicrobial stewardship in the feedlot. Vet Clin North Am Food Anim Pract. 2015;31(1):127-139.